Literature DB >> 19029956

Insulin and insulin-like growth factor signalling in neoplasia.

Michael Pollak1.   

Abstract

Insulin and insulin-like growth factors (IGFs) are well known as key regulators of energy metabolism and growth. There is now considerable evidence that these hormones and the signal transduction networks they regulate have important roles in neoplasia. Epidermiological, clinical and laboratory research methods are being used to investigate novel cancer prevention and treatment strategies related to insulin and IGF signalling. Pharmacological strategies under study include the use of novel receptor-specific antibodies, receptor kinase inhibitors and AMP-activated protein kinase activators such as metformin. There is evidence that insulin and IGF signalling may also be relevant to dietary and lifestyle factors that influence cancer risk and cancer prognosis. Recent results are encouraging and have justified the expansion of many translational research programmes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19029956     DOI: 10.1038/nrc2536

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  823 in total

1.  Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy.

Authors:  Danielle B Ulanet; Dale L Ludwig; C Ronald Kahn; Douglas Hanahan
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-10       Impact factor: 11.205

2.  Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development.

Authors:  Todd M Pitts; Aik Choon Tan; Gillian N Kulikowski; John J Tentler; Amy M Brown; Sara A Flanigan; Stephen Leong; Christopher D Coldren; Fred R Hirsch; Marileila Varella-Garcia; Christopher Korch; S Gail Eckhardt
Journal:  Clin Cancer Res       Date:  2010-06-08       Impact factor: 12.531

3.  Association of insulin and insulin-like growth factors with Barrett's oesophagus.

Authors:  Katarina B Greer; Cheryl L Thompson; Lacie Brenner; Beth Bednarchik; Dawn Dawson; Joseph Willis; William M Grady; Gary W Falk; Gregory S Cooper; Li Li; Amitabh Chak
Journal:  Gut       Date:  2011-09-19       Impact factor: 23.059

4.  Serum IGF1, IGF2 and IGFBP3 and risk of advanced colorectal adenoma.

Authors:  Ying Gao; Hormuzd Katki; Barry Graubard; Michael Pollak; Michael Martin; Yuzhen Tao; Robert E Schoen; Timothy Church; Richard B Hayes; Mark H Greene; Sonja I Berndt
Journal:  Int J Cancer       Date:  2011-11-02       Impact factor: 7.396

5.  Diabetes mellitus and incidence of kidney cancer: a meta-analysis of cohort studies.

Authors:  S C Larsson; A Wolk
Journal:  Diabetologia       Date:  2011-01-28       Impact factor: 10.122

Review 6.  Obesity, energy balance, and cancer: new opportunities for prevention.

Authors:  Stephen D Hursting; John Digiovanni; Andrew J Dannenberg; Maria Azrad; Derek Leroith; Wendy Demark-Wahnefried; Madhuri Kakarala; Angela Brodie; Nathan A Berger
Journal:  Cancer Prev Res (Phila)       Date:  2012-10-03

Review 7.  Diabetes and gastric cancer: the potential links.

Authors:  Chin-Hsiao Tseng; Farn-Hsuan Tseng
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

8.  High glucose modulates antiproliferative effect and cytotoxicity of 5-fluorouracil in human colon cancer cells.

Authors:  Yi-Shing Ma; I-Ping Yang; Hsiang-Lin Tsai; Ching-Wen Huang; Suh-Hang Hank Juo; Jaw-Yuan Wang
Journal:  DNA Cell Biol       Date:  2013-11-27       Impact factor: 3.311

Review 9.  Hereditary diffuse gastric cancer: What the clinician should know.

Authors:  Ryan Ying Cong Tan; Joanne Ngeow
Journal:  World J Gastrointest Oncol       Date:  2015-09-15

10.  Metformin use and its effect on gastric cancer in patients with type 2 diabetes: A systematic review of observational studies.

Authors:  Peiwen Li; Cong Zhang; Peng Gao; Xiaowan Chen; Bin Ma; Dehao Yu; Yongxi Song; Zhenning Wang
Journal:  Oncol Lett       Date:  2017-11-08       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.